研究会のご案内
リエゾンラボ研究会
発表内容

Title:
Development of Transdermal Drug Delivery System (TDDS)

Naruhito Higo
Hisamitsu Pharmaceutical Co., Inc.

Abstract:
 The potential of TDDS (Transdermal Drug Delivery System) has been demonstrated in recent years with the approval of several pharmaceutical products for patients with difficulty in using conventional dosage forms like oral administration or injection. To enhance the TDDS potential to include other drug candidates, many researchers have been exploring enhancement approaches to increase the permeability of various drugs through the skin.1)
As the first approach, chemical penetration enhancers have been investigated for decades and practically used in some TDDS products available in the market.2) Among these products, we have launched out Mohrus®Tape, Estrana®, Fentos®Tape and Neoxy®Tape in our history and these have been used by many patients.
On the other hand, physical enhancement systems are being reported as the potent delivery methods by numerous researchers. Specifically, iontophoresis is a very attractive way to deliver ionized drugs transdermally by the application of an electric field to the skin.3) This has been marketed with a few topical and systemic drugs (lidocaine and fentanyl). Sonophoresis is also an attractive method to deliver a drug through the skin using ultrasound.4) Besides these technologies, various physical approaches are under the studies. Such technology can be expected to deliver not only small MW compounds but also macromolecules like proteins and vaccines. Especially, microneedles pierce only the stratum corneum and create new pathways for drug transport when applied to the skin, so that proteins and vaccines can be delivered to the therapeutic levels through the skin without pain and discomfort.5) In this session, after looking back through the history of TDDS development, I would like to summarize new physical and chemical approaches and outline how we can overcome some of the critical hurdles in TDDS development to improve patient Q.O.L.

References:
1) Prausnitz MR, Mitragotri S, Langer R. Nat Rev Drug Discov. 3(2):115-24 (2004)
2) Williams AC, Barry BW. Adv Drug Deliv Rev. 56(5):603-18 (2004).
3) Kalia YN, Naik A, Garrison J, Guy RH. Adv Drug Deliv Rev. 56(5):619-58 (2004).
4) Mitragotri S. Nat Rev Drug Discov. 4(3):255-60 (2005).
5) Prausnitz MR. Adv Drug Deliv Rev. 56(5):581-7 (2004).